KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $789,000.

  • Rigel Pharmaceuticals' Change in Accured Expenses fell 88.51% to $789,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 121.03%. This contributed to the annual value of $5.0 million for FY2024, which is 533.97% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Change in Accured Expenses stood at $789,000, which was down 57.88% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Change in Accured Expenses ranged from a high of $57.9 million in Q1 2021 and a low of -$59.7 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $672,000 (2023), whereas its average is $217,364.
  • Examining YoY changes over the last 5 years, Rigel Pharmaceuticals' Change in Accured Expenses showed a top increase of 1,848.19% in 2021 and a maximum decrease of 3,444.23% in 2021.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Change in Accured Expenses stood at -$1.5 million in 2021, then slumped by 78.91% to -$2.6 million in 2022, then spiked by 111.60% to $304,000 in 2023, then soared by 41.12% to $429,000 in 2024, then slumped by 88.51% to $789,000 in 2025.
  • Its Change in Accured Expenses was $789,000 in Q3 2025, compared to $1.9 million in Q2 2025 and -$4.1 million in Q1 2025.